Trials / Completed
CompletedNCT05501639
Exacerbation Risk in Asthma
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,899 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to conduct a comparative analysis of patients using Tiotropium in combination with Inhaled Corticosteroids (ICS) versus those that use long-acting β2-agonists (LABA) medication in combination with ICS.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tiotropium | tiotropium |
| DRUG | long-acting β2-agonists (LABA) | long-acting β2-agonists (LABA) |
| DRUG | inhaled corticosteroids (ICS) | inhaled corticosteroids (ICS) |
Timeline
- Start date
- 2021-05-14
- Primary completion
- 2021-11-02
- Completion
- 2021-11-02
- First posted
- 2022-08-15
- Last updated
- 2024-04-01
- Results posted
- 2024-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05501639. Inclusion in this directory is not an endorsement.